Adrenomedullin has a role in angiogenic effects of resveratrol in adipose tissues of obese female rats

  • Ayse Asiye CulumEmail author
  • Muhittin Yurekli
Original Article


Obesity is a complex, chronic disease that arises according to the interaction between genetic and environmental factors. The expansion and growth of white adipose tissue (WAT) could be related to angiogenesis. Resveratrol and adrenomedullin (AdM) were used for the inhibition of angiogenesis in metabolically passive WAT for inhibiting the expansion of this tissue, and the activation of angiogenesis in metabolically active brown adipose tissue (BAT) for increasing daily energy consumption as a way of reducing obesity. Rats were divided into eight groups. Four obese groups were fed with a high-fat diet containing 60% fat as energy for three months. After obtaining obesity, 2.5 nmol/kg AdM and 10 mg/kg resveratrol were treated to experiment groups intraperitoneally (i.p.) every other day for four weeks. AdM and vascular endothelial growth factor A (VEGF-A) mRNA levels were detected with semi-quantitative PCR; protein levels were detected with Western Blotting. AdM and resveratrol are multifactorial molecules, thus, this study has revealed a few novel evidence. The results were distinct in the group and treatment levels. The results showed that resveratrol has a role in angiogenesis in obesity and contributed to AdM production. It is observed that AdM has regulated its expression and increased the effect of resveratrol in WAT. AdM and VEGF-A gene expressions could not be detected in BAT; however, it is suggested that resveratrol may have a pro-angiogenic effect in BAT of obese rats according to the protein levels. AdM also has regulated VEGF-A level according to the metabolic situation of the organism.


Obesity VEGF-A Adrenomedullin Resveratrol Brown adipose tissue White adipose tissue 



This research was funded by Inonu University, Department of Scientific Research Projects (Project No: 2016/153).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interests.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.


  1. 1.
    Frühbeck G, Becerril S, Sáinz N et al (2009) BAT: a new target for human obesity? Trends Pharmacol Sci 30:387–396. CrossRefPubMedGoogle Scholar
  2. 2.
    Miao C-Y, Li Z-Y (2012) The role of perivascular adipose tissue in vascular smooth muscle cell growth. Br J Pharmacol 165:643–658. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Cao Y (2007) Angiogenesis modulates adipogenesis and obesity. J Clin Invest 117:2362–2368. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Zygmunt M, Herr F, Münstedt K et al (2003) Angiogenesis and vasculogenesis in pregnancy. Eur J Obstet Gynecol Reprod Biol 110:S10-8. CrossRefPubMedGoogle Scholar
  5. 5.
    Risau W (1997) Mechanisms of angiogenesis. Nature 386:671–674. CrossRefPubMedGoogle Scholar
  6. 6.
    Folkman J (2006) Angiogenesis. Annu Rev Med 57:1–18. CrossRefPubMedGoogle Scholar
  7. 7.
    Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795–803. CrossRefPubMedGoogle Scholar
  8. 8.
    Ferrara N (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280:C1358–C1366. CrossRefPubMedGoogle Scholar
  9. 9.
    Kitamura K, Kangawa K, Kawamoto M et al (1993) Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192:553–560. CrossRefPubMedGoogle Scholar
  10. 10.
    Martinez A, Miller MJ, Unsworth EJ et al (1995) Expression of adrenomedullin in normal human lung and in pulmonary tumors. Endocrinology 136:4099–4105. CrossRefPubMedGoogle Scholar
  11. 11.
    Samson WK (1999) Adrenomedullin and the control of fluid and electrolyte homeostasis. Annu Rev Physiol 61:363–389. CrossRefPubMedGoogle Scholar
  12. 12.
    Li Y, Totsune K, Takeda K et al (2003) Differential expression of adrenomedullin and resistin in 3T3-L1 adipocytes treated with tumor necrosis factor-alpha. Eur J Endocrinol 149:231–238. CrossRefPubMedGoogle Scholar
  13. 13.
    Nambu T, Arai H, Komatsu Y et al (2005) Expression of the adrenomedullin gene in adipose tissue. Regul Pept 132:17–22. CrossRefPubMedGoogle Scholar
  14. 14.
    Allaker R (1999) An investigation into the antimicrobial effects of adrenomedullin on members of the skin, oral, respiratory tract and gut microflora. FEMS Immunol Med Microbiol 23:289–293. CrossRefPubMedGoogle Scholar
  15. 15.
    Sugo S, Minamino N, Shoji H et al (1995) Interleukin-1, tumor necrosis factor and lipopolysaccharide additively stimulate production of adrenomedullin in vascular smooth muscle cells. Biochem Biophys Res Commun 207:25–32. CrossRefPubMedGoogle Scholar
  16. 16.
    Fukai N, Yoshimoto T, Sugiyama T et al (2005) Concomitant expression of adrenomedullin and its receptor components in rat adipose tissues. Am J Physiol Endocrinol Metab 288:E56–E62. CrossRefPubMedGoogle Scholar
  17. 17.
    Kato J, Kitamura K, Uemura T et al (2002) Plasma levels of adrenomedullin and atrial and brain natriuretic peptides in the general population: their relations to age and pulse pressure. Hypertens Res 25:887–892. CrossRefPubMedGoogle Scholar
  18. 18.
    Amri A, Chaumeil JC, Sfar S, Charrueau C (2012) Administration of resveratrol: what formulation solutions to bioavailability limitations? J Control Release 158:182–193. CrossRefPubMedGoogle Scholar
  19. 19.
    Szabó G (2009) A glass of red wine to improve mitochondrial biogenesis? Novel mechanisms of resveratrol. Am J Physiol Circ Physiol 297:H8–H9. CrossRefGoogle Scholar
  20. 20.
    Sielmann EH, Creasy LL (1992) Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic 43:49–52Google Scholar
  21. 21.
    Baur JA, Pearson KJ, Price NL et al (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337–342. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Rayalam S, Yang J-Y, Ambati S et al (2008) Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phyther Res 22:1367–1371. CrossRefGoogle Scholar
  23. 23.
    Schwartz MW, Woods SC, Seeley RJ et al (2003) Is the energy homeostasis system ınherently biased toward weight gain? Diabetes 52:232–238. CrossRefPubMedGoogle Scholar
  24. 24.
    Abizaid A, Gao Q, Horvath TL (2006) Thoughts for food: brain mechanisms and peripheral energy balance. Neuron 51:691–702. CrossRefPubMedGoogle Scholar
  25. 25.
    Carey AL, Kingwell BA (2013) Brown adipose tissue in humans: therapeutic potential to combat obesity. Pharmacol Ther 140:26–33. CrossRefPubMedGoogle Scholar
  26. 26.
    Gesta S, Tseng Y-H, Kahn CR et al (2007) Developmental origin of fat: tracking obesity to its source. Cell 131:242–256. CrossRefPubMedGoogle Scholar
  27. 27.
    Oberkofler H, Dallinger G, Liu YM et al (1997) Uncoupling protein gene: quantification of expression levels in adipose tissues of obese and non-obese humans. J Lipid Res 38:2125–2133PubMedGoogle Scholar
  28. 28.
    Stefl B, Janovská A, Hodný Z et al (1998) Brown fat is essential for cold-induced thermogenesis but not for obesity resistance in aP2-Ucp mice. Am J Physiol Endocrinol Metab 274:E527–E533. CrossRefGoogle Scholar
  29. 29.
    Grundlingh J, Dargan PI, El-Zanfaly M, Wood DM (2011) 2,4-Dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of death. J Med Toxicol 7:205–212. CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Brakenhielm E, Cao R, Gao B et al (2004) Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ Res 94:1579–1588. CrossRefPubMedGoogle Scholar
  31. 31.
    O’Reilly MS, Holmgren L, Shing Y et al (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315–328. CrossRefPubMedGoogle Scholar
  32. 32.
    O’Reilly MS, Boehm T, Shing Y et al (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285. CrossRefPubMedGoogle Scholar
  33. 33.
    Hariri N, Thibault L (2010) High-fat diet-induced obesity in animal models. Nutr Res Rev 23:270–299. CrossRefPubMedGoogle Scholar
  34. 34.
    Harrold JA, Williams G, Widdowson PS (2000) Early leptin response to a palatable diet predicts dietary obesity in rats: key role of melanocortin-4 receptors in the ventromedial hypothalamic nucleus. J Neurochem 74:1224–1228. CrossRefPubMedGoogle Scholar
  35. 35.
    Woods SC, Seeley RJ, Rushing PA et al (2003) A controlled high-fat diet induces an obese syndrome in rats. J Nutr 133:1081–1087. CrossRefPubMedGoogle Scholar
  36. 36.
    Hwang ISS, Fung ML, Liong EC et al (2007) Age-related changes in adrenomedullin expression and hypoxia-inducible factor-1 activity in the rat lung and their responses to hypoxia. J Gerontol A Biol Sci Med Sci 62A:41–49. CrossRefGoogle Scholar
  37. 37.
    Li Y-Y, Hwang IS, WS O, Tang F (2006) Adrenomedullin peptide: gene expression of adrenomedullin, its receptors and receptor activity modifying proteins, and receptor binding in rat testis–actions on testosterone secretion. Biol Reprod 75:183–188. CrossRefPubMedGoogle Scholar
  38. 38.
    Chen S, Chakrabarti R, Keats EC et al (2012) Regulation of vascular endothelial growth factor expression by extra domain B segment of fibronectin in endothelial cells. Investig Ophthalmol Vis Sci 53:8333–8343. CrossRefGoogle Scholar
  39. 39.
    Untergasser A, Cutcutache I, Koressaar T et al (2012) Primer3-new capabilities and interfaces. Nucleic Acids Res 40:1–12. CrossRefGoogle Scholar
  40. 40.
    Cheyuo C, Yang W, Wang P (2012) The critical role of adrenomedullin and its binding protein, AMBP-1, in neuroprotection. Biol Chem 393:429–439. CrossRefPubMedGoogle Scholar
  41. 41.
    Yurekli M, Culum AA (2016) The investigation of relationship between adrenomedullin vascular growth endothelial factor in obese and calorie restricted rats. Med Sci Discov 3:124–129CrossRefGoogle Scholar
  42. 42.
    Lagouge M, Argmann C, Gerhart-Hines Z et al (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127:1109–1122. CrossRefPubMedGoogle Scholar
  43. 43.
    Eto T, Kato J, Kitamura K (2003) Regulation of production and secretion of adrenomedullin in the cardiovascular system. Regul Pept 112:61–69. CrossRefPubMedGoogle Scholar
  44. 44.
    Bertelli AAE (2007) Wine, research and cardiovascular disease: Instructions for use. Atherosclerosis 195:242–247. CrossRefPubMedGoogle Scholar
  45. 45.
    Cao Y (2010) Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases. Nat Rev Drug Discov 9:107–115. CrossRefPubMedGoogle Scholar
  46. 46.
    Rupnick MA, Panigrahy D, Zhang C-Y et al (2002) Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci 99:10730–10735. CrossRefPubMedGoogle Scholar
  47. 47.
    Chen Y, Sheng-Hong T (2007) Review. Pro- and anti-angiogenesis effects of resveratrol. In Vivo 21:365–370PubMedGoogle Scholar
  48. 48.
    Distler JHW, Hirth A, Kurowska-Stolarska M et al (2003) Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 47:149–161PubMedGoogle Scholar
  49. 49.
    Duarte D, Santos-Araújo C, Leite-Moreira AF (2011) Hypertension and angiogenesis in the aging kidney: a review. Arch Gerontol Geriatr 52:e93–e102. CrossRefPubMedGoogle Scholar
  50. 50.
    Arcondeguy T, Lacazette E, Millevoi S et al (2013) VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level. Nucleic Acids Res 41:7997–8010. CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Ishii H, Oota I, Arakawa T, Takuma T (2002) Differential gene expression of vascular endothelial growth factor isoforms and their receptors in the development of the rat masseter muscle. Arch Oral Biol 47:505–510. CrossRefPubMedGoogle Scholar
  52. 52.
    Guidolin D, Albertin G, Spinazzi R et al (2008) Adrenomedullin stimulates angiogenic response in cultured human vascular endothelial cells: involvement of the vascular endothelial growth factor receptor 2. Peptides 29:2013–2023. CrossRefPubMedGoogle Scholar
  53. 53.
    Evans JJ, Chitcholtan K, Dann JM et al (2012) Adrenomedullin interacts with VEGF in endometrial cancer and has varied modulation in tumours of different grades. Gynecol Oncol 125:214–219. CrossRefPubMedGoogle Scholar
  54. 54.
    Palmer BF, Clegg DJ (2015) The sexual dimorphism of obesity. Mol Cell Endocrinol 402:113–119. CrossRefPubMedGoogle Scholar
  55. 55.
    Aubin M, Lajoie C, Cle R et al (2008) Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J Pharmacol Exp Ther 325:961–968. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2020

Authors and Affiliations

  1. 1.Department of Biology, The Faculty of Science and LiteratureInonu UniversityMalatyaTurkey

Personalised recommendations